Parmax Pharma Ltd. (PARMAX) — Tipsheet

Parmax Pharma's new owners are taking over. They're paying ₹42.80 a share.

Tipsheet Editorial — Tue, 09 Jun 2026 08:53:02 GMT

Dhiren and Sunil Shah, with a consortium of ten others, are paying ₹18.6 crore to take ~91% control of the struggling nano-cap, which saw revenues collapse 57% and losses widen.

What’s new

Consortium led by Dhiren and Sunil Shah launched an open offer to acquire up to 26% of Parmax Pharma at ₹42.80 a share.
The bid follows a ₹35-per-share purchase of 11.52 lakh shares from current promoters and a preferential issue at ₹36.50.
The combined deal value is ~₹18.6 crore, which exceeds the company's entire ₹18 crore market cap.

Why it matters

This is a textbook nano-cap takeover. A consortium is acquiring effective control for less than the company's market value, injecting new capital into a business that has shed more than half its revenue. For a ₹18 crore company, the transaction size is the news. It's a complete handover, not a minority stake.

What we’re watching

Whether the open offer gets the full 26% acceptance it's sized for.
How the new management team plans to reverse the 57% revenue decline.
The timeline for completing the share purchase and preferential issue.

The full read

Parmax Pharma is changing hands. A consortium led by Dhiren and Sunil Shah is spending ₹18.6 crore to take roughly 91% control of the ₹18 crore nano-cap. The deal is structured in three parts: a ₹35-per-share purchase of 11.52 lakh shares from the current promoters, a preferential issue at ₹36.50, and a public open offer for up to 26% at ₹42.80. The acquirers are paying a premium at each successive stage, signalling intent. The target is a business in deep trouble, with revenues down 57% and losses widening. For the incoming group, this is an inexpensive way to gain a listed shell and inject capital. The entire acquisition cost is less than the company's market value. What changes from here is whether the new owners can reverse the operating decline.

Primary source: BSE · NSE

Parmax Pharma raises ₹19.28 cr, hands control to 14 new investors

Tipsheet Editorial — Mon, 08 Jun 2026 15:24:19 GMT

The raise is worth 113% of the company's ₹17 cr market cap. The new allottees will become majority owners.

What’s new

Board approved issuing 31.4 lakh shares and 21.5 lakh warrants at ₹36.50 each to raise ₹19.28 cr.
The allottees, led by Dhiren and Sunil Shah, will become majority owners.
The raise follows a 57% revenue decline and auditor-flagged governance red flags.

Why it matters

This isn't a routine capital raise. A ₹19.28 cr infusion into a company with a ₹17 cr market cap is a takeover in all but name. The new investors are taking control of a business in distress, betting the governance issues and collapsing revenue can be fixed with fresh capital and new ownership.

What we’re watching

Whether minority shareholders approve the issue at the July 2 EGM.
The timeline for the new control group to execute a turnaround.
Whether auditor governance concerns are resolved post-change of control.

The full read

Parmax Pharma is raising ₹19.28 crore through a preferential issue that will hand majority control to 14 new investors. That's the headline, but the context is what matters. The raise is worth 113% of the company's ₹17 crore market cap. The business is in distress, with a 57% revenue decline, widening losses, and auditors who have already flagged governance red flags. The new control group, led by Dhiren and Sunil Shah, is taking over a company worth less than the cash it's putting in. The issue price of ₹36.50 a share carries a premium over recent trading, but the authorized share capital has to be expanded from ₹6 crore to ₹10 crore just to fit the new stock. Shareholder approval at a July 2 EGM is the next gate.

Primary source: BSE · NSE

Parmax Pharma turns to a preferential issue after a 57% revenue crash.

Tipsheet Editorial — Wed, 03 Jun 2026 21:18:52 GMT

A nano-cap with a ₹14 crore market cap, ₹4.16 crore in annual losses, and auditors flagging the Managing Director's fund use is seeking fresh equity.

What’s new

Parmax Pharma's board will meet June 8 to evaluate a preferential issue of shares.
Auditors flagged the Managing Director's unauthorized use of company funds.
Annual revenue fell 57% and net losses widened to ₹4.16 crore.

Why it matters

This isn't a growth raise. It's a nano-cap with a collapsing business and an auditor flagging its MD. A preferential issue here is likely a survival move or a path to a control change, executed from a position of deep weakness.

What we’re watching

The identity and price of the preferential issue subscribers.
Whether the auditor's governance findings lead to regulatory action.
The terms of the shareholder EGM sought for approval.

The full read

Parmax Pharma's board meets on June 8 to weigh a preferential issue. The backdrop is grim. Revenue fell 57% last year. The net loss widened to ₹4.16 crore. The company's entire market cap is ₹14 crore. Worse, auditors have questioned how the Managing Director used company funds. For a nano-cap, this is not a routine capital raise. It's a lifeline, or a prelude to a control change. The price of the new shares and who buys them will define the outcome. The company is seeking shareholder approval, but the core signal is simple: Parmax needs money it doesn't have. The raise is a necessity, executed under a cloud of audit findings.

Primary source: BSE · NSE

Parmax Pharma revenue halved, auditors flag MD's use of company funds

Tipsheet Editorial — Wed, 03 Jun 2026 18:47:55 GMT

FY26 revenue fell 57% to ₹12.11 crore as auditors qualified the accounts over unauthorized mutual fund purchases in the managing director's name.

What’s new

Annual revenue fell 57% to ₹12.11 crore from ₹28.20 crore in FY25.
Net loss doubled to ₹4.16 crore from ₹2.09 crore a year earlier.
Auditors qualified the accounts over unauthorized company funds used for mutual funds in the MD's name.

Why it matters

A qualified audit opinion for a company this small is not routine. It means the auditors found specific, material violations of the Companies Act and accounting standards that the board has not fixed. For a nano-cap with a ₹14 crore market value, these governance issues now overshadow the operational collapse.

What we’re watching

Whether the board or SEBI acts on the auditor's findings about the MD.
The company's plan to restate accounts and address the ₹40 lakh mutual fund transaction.
Any movement in the stock after the qualified opinion becomes public.

The full read

Parmax Pharma's fiscal year was defined by collapse. Revenue plunged 57% to ₹12.11 crore. The net loss doubled to ₹4.16 crore. But the real problem is in the auditor's report. The auditors qualified the accounts, meaning they found specific, material violations they could not reconcile. Chief among them: ₹40 lakhs of company money were used to buy mutual funds held in the managing director's name, a direct breach of Section 187 of the Companies Act. Separately, the company skipped depreciation on over ₹2 crore in plant assets and used cash-basis accounting for employee benefits, which violates accounting standards. For a company with a ₹14 crore market value, these aren't footnotes. They are the story.

Primary source: BSE · NSE